Drug Profile
GW 328267
Alternative Names: 328267; GW-328267X; GW328267Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiallergics
- Mechanism of Action Adenosine A2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 01 Dec 2004 Discontinued - Phase-I for Asthma in Netherlands (Inhalation)
- 01 Dec 2004 Discontinued - Phase-II for Allergic rhinitis in United Kingdom (unspecified route)
- 01 Dec 2004 Discontinued - Phase-II for Asthma in United Kingdom (Inhalation)